Th1 and Th2 Cell Involvement in Immune Response to Salmonella Typhimurium Porins
Overview
Affiliations
In understanding the regulation of the specific immune response to Salmonella typhimurium, the role of a surface major component (porins) was studied. In this study we demonstrate that purified porins are able to induce a different response to that induced by the porins present on the S. typhimurium cell surface. Porin-treated or orally infected mice show anti-porin antibodies with bactericidal activity. The complete adoptive transfer of resistance to S. typhimurium is achieved only using splenic T cells from survivor mice after experimental infection. After stimulation with specific antigen in vitro CD4+ cells from porin-immunized mice released large amounts of interleukin-4 (IL-4), at a time when CD4+ cells from S. typhimurium-infected mice predominantly secreted interferon-gamma (IFN-gamma). Limiting dilution analysis showed that infection resulted in a higher precursor frequency of IFN-gamma-producing CD4+ T cells and a lower precursor frequency of IL-4-producing CD4+ T cells, while immunization with porins resulted in a higher precursor frequency of IL-4-producing cells and a low frequency of IFN-gamma-producing cells. Analysis of polymerase chain reaction-amplified cDNA from the spleens of infected mice revealed that IFN-gamma, IL-2 and IL-12 p40 mRNA were found 5 days after in vitro challenge and increased after 15 days; IL-10 expression was barely present after both 5 and 15 days, while IL-4 mRNA expression was not detected. In immunized mice, the IL-4 mRNA expression increased after 15 days, IFN-gamma mRNA expression disappeared entirely after 15 days, while IL-2, IL-10 and IL-12 mRNA remained relatively unchanged.
Praveen C, Bhatia S, Alaniz R, Droleskey R, Cohen N, Jesudhasan P PLoS One. 2021; 16(4):e0243417.
PMID: 33861743 PMC: 8051754. DOI: 10.1371/journal.pone.0243417.
Surface engineered polyanhydride-based oral subunit nanovaccine for poultry.
Renu S, Markazi A, Dhakal S, Lakshmanappa Y, Gourapura S, Shanmugasundaram R Int J Nanomedicine. 2018; 13:8195-8215.
PMID: 30555234 PMC: 6280892. DOI: 10.2147/IJN.S185588.
Cantisani M, Vitiello M, Falanga A, Finamore E, Galdiero M, Galdiero S Int J Nanomedicine. 2012; 7:2361-71.
PMID: 22654515 PMC: 3363952. DOI: 10.2147/IJN.S30467.
Liu T, Chopra A Cancer Gene Ther. 2009; 17(2):97-108.
PMID: 19713997 PMC: 2808459. DOI: 10.1038/cgt.2009.58.
Chinombe N, Bourn W, Williamson A, Shephard E Virol J. 2009; 6:87.
PMID: 19555490 PMC: 2708135. DOI: 10.1186/1743-422X-6-87.